MOWI

In the global contest for premium animal protein, one company controls more of the value chain than any other. Mowi ASA, headquartered in Bergen, Norway, is the world's largest producer of farmed Atlantic salmon by volume, operating across 25 countries with approximately 11,500 employees and a market capitalization of roughly NOK 112 billion (approximately EUR 10.7 billion). The company's three operating segments, Feed, Farming, and Sales and Marketing, together form a vertically integrated architecture that no competitor has fully replicated. This is not a commodity producer that happens to be large. This is the company that sets the biological, logistical, and pricing baseline for an entire global protein category.

The central analytical question for Mowi is deceptively simple: can a company whose core product is a living organism, raised in environments subject to disease, regulation, and climate variability, sustain the kind of structural market power normally reserved for technology platforms or pharmaceutical franchises? The answer, visible in both the financial data and the competitive landscape, is that Mowi has engineered a moat not from any single advantage but from the compounding interaction of multiple advantages that function together as a system. Licensed fjord capacity in Norway, Scotland, Canada, and Chile is finite and expanding only marginally. Feed production, through the company's dedicated feed segment, internalizes the single largest cost input in salmon farming. And a global sales and marketing operation, including secondary processing facilities across Europe and the Americas, converts raw biological output into branded, value-added products that command premium pricing.

Revenue reached EUR 5.72 billion in FY2025, up from EUR 4.17 billion in 2021, representing a compound annual growth rate of roughly 8.2%. Net income for FY2025 was EUR 717.9 million, with EPS of EUR 1.38, a significant recovery from the EUR 0.86 and EUR 0.91 recorded in 2023 and 2024 respectively. The earnings trajectory is not smooth; it never is in aquaculture. But the structural direction is unmistakable. Analyst consensus projects revenue climbing to EUR 6.79 billion in 2026 and EUR 7.56 billion by 2028, with EPS estimates reaching EUR 1.83 in 2028. The question is not whether Mowi will grow. The question is whether the regulatory, biological, and political forces arrayed against salmon farming can erode the structural advantages that make Mowi the defining entity in its market.